ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 117 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $417,955 | -38.2% | 78,711 | +10.8% | 0.00% | – |
| Q2 2023 | $676,706 | +11.9% | 71,008 | +29.0% | 0.00% | – |
| Q1 2023 | $605,000 | +91566.7% | 55,039 | +23.4% | 0.00% | – |
| Q4 2022 | $660 | -99.9% | 44,608 | +2.4% | 0.00% | – |
| Q3 2022 | $833,000 | +18.0% | 43,546 | +31.5% | 0.00% | – |
| Q2 2022 | $706,000 | +35.8% | 33,112 | +22.5% | 0.00% | – |
| Q1 2022 | $520,000 | +12.1% | 27,022 | +20.8% | 0.00% | – |
| Q4 2021 | $464,000 | -4.1% | 22,376 | +10.2% | 0.00% | – |
| Q3 2021 | $484,000 | -8.9% | 20,296 | +4.4% | 0.00% | – |
| Q2 2021 | $531,000 | +23.5% | 19,434 | +30.9% | 0.00% | – |
| Q1 2021 | $430,000 | +64.1% | 14,852 | +59.3% | 0.00% | – |
| Q4 2020 | $262,000 | +25.4% | 9,325 | +38.4% | 0.00% | – |
| Q3 2020 | $209,000 | +117.7% | 6,739 | +110.7% | 0.00% | – |
| Q2 2020 | $96,000 | -4.0% | 3,199 | -4.5% | 0.00% | – |
| Q1 2020 | $100,000 | – | 3,351 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |